查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1519373

2024-2032 年按類型、疾病類型、分子類型、藥物類型、給藥途徑、配銷通路和地區分類的潰瘍性結腸炎市場報告

Ulcerative Colitis Market Report by Type, Disease Type, Molecule Type, Drug Type, Route of Administration, Distribution Channel, and Region 2024-2032
出版日期: | 出版商: IMARC | 英文 136 Pages | 商品交期: 2-3個工作天內

價格

2023年全球潰瘍性結腸炎IMARC Group規模達78億美元。由於疾病盛行率上升、醫療進步、政府支持政策以及全球意識的提高，潰瘍性結腸炎市場正在擴大，這些都推動了發達和發展中地區對創新療法的需求。

潰瘍性結腸炎市場分析：

主要市場促進因素：全球潰瘍性結腸炎數量激增，以及人們對發炎性腸道疾病存在的認知，刺激了患者對創新治療和診斷方法的需求。此外，技術進步、生物製劑的擴展和新療法的發明加強了市場發展。已開發國家和發展中國家不斷成長的醫療保健支出也促進了市場擴大。

主要市場趨勢：治療潰瘍性結腸炎的個人化醫療趨勢日益明顯，強調基於遺傳、環境和表現型特徵的客製化治療方法。此外，擴大採用生物製劑和生物相似藥來治療重症病例，正在顯著影響該市場製藥業的方向。

地理趨勢：由於先進的醫療設施、高醫療支出和成熟的製藥公司，北美引領潰瘍性結腸炎市場。然而，鑑於以中國和印度等地區為中心的醫療設施、患者意識和醫療旅遊的增加，預計亞太地區將以顯著的速度發展。

競爭格局：潰瘍性結腸炎產業的一些主要市場參與者包括雅培實驗室、艾伯維公司、阿斯特捷利康公司、百時美施貴寶公司、禮來公司、羅氏有限公司、葛蘭素史克公司、強生公司強生、默克、輝瑞、武田製藥有限公司及梯瓦製藥工業有限公司等。

挑戰與機會：市場的主要挑戰是治療成本高昂，這可能會對低收入國家的取得造成障礙，特別是在涉及生物製劑時。另一個因素是勞動密集且漫長的藥物核准過程，這可能會延遲新療法進入市場。儘管挑戰很嚴峻，但挑戰可以成為機會的基礎。開發具有成本效益的療法並簡化核准流程可以使全球企業受益。

潰瘍性結腸炎市場趨勢：

潰瘍性結腸炎的盛行率增加

潰瘍性結腸炎盛行率的成長以及人們對發炎性腸道疾病存在的認知的傳播刺激了患者對創新治療和診斷方法的需求。此外，技術進步、生物製劑的擴展和新療法的發明加強了市場發展。已開發國家和發展中國家不斷成長的醫療保健支出也促進了市場擴大。根據國家醫學圖書館的數據，潰瘍性結腸炎的發生率為每年每 10 萬人中 9 至 20 例。其盛行率為每年每 10 萬人 156 至 291 例。

醫學治療的進步

隨著生物製劑和小分子藥物的發展，潰瘍性結腸炎的醫學治療取得了長足的進展。這項進展所帶來的正面精神，創造了更多有利的市場相關因素。一方面，診斷技術的進步和新的標靶治療方法的開發對市場產生了積極影響，因為更有效的治療方法的開發推動了採用率的增加。例如，輝瑞公司於2023 年宣布，美國食品藥物管理局(FDA) 已批准VELSIPITY(TM) (etrasimod)，這是一種口服、每日一次的選擇性1-磷酸鞘氨醇(S1P) 受體調節劑，用於成人中度至重度活動性潰瘍性結腸炎（UC）。

政府和監管支持

有利的政府政策和醫療保健支出的增加極大地影響了潰瘍性結腸炎市場的成長。隨著監管部門的批准促進新的有效藥物快速進入市場，患者可以獲得先進的治療選擇。此外，一些政府增加了研發資金，鼓勵製藥公司投資潰瘍性結腸炎的創新療法，這進一步刺激了市場成長。

目錄

第1章：前言

第 2 章：範圍與方法

  • 研究目的
  • 利害關係人
  • 資料來源
    • 主要資源
    • 二手資料
  • 市場預測
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第 3 章：執行摘要

第 4 章：簡介

  • 概述
  • 主要行業趨勢

第 5 章：全球潰瘍性結腸炎市場

  • 市場概況
  • 市場業績
  • COVID-19 的影響
  • 市場預測

第 6 章：市場區隔：按類型

  • 輕度UC
    • 市場走向
    • 市場預測
  • 中度UC
    • 市場走向
    • 市場預測
  • 嚴重潰瘍性結腸炎
    • 市場走向
    • 市場預測

第 7 章：市場區隔：依疾病類型

  • 潰瘍性直腸炎
    • 市場走向
    • 市場預測
  • 直腸乙狀結腸炎
    • 市場走向
    • 市場預測
  • 左側結腸炎
    • 市場走向
    • 市場預測
  • 全結腸炎或普遍性結腸炎
    • 市場走向
    • 市場預測
  • 暴發性結腸炎
    • 市場走向
    • 市場預測

第 8 章：市場區隔：依分子類型

  • 小分子
    • 市場走向
    • 市場預測
  • 生物製劑
    • 市場走向
    • 市場預測

第 9 章：市場區隔：依藥物類型

  • 抗發炎藥
    • 市場走向
    • 市場預測
  • 抗腫瘤壞死因子生物製劑
    • 市場走向
    • 市場預測
  • 免疫抑制劑
    • 市場走向
    • 市場預測
  • 鈣調磷酸酶抑制劑
    • 市場走向
    • 市場預測
  • 其他
    • 市場走向
    • 市場預測

第 10 章：市場區隔：依管理途徑

  • 口服
    • 市場走向
    • 市場預測
  • 可注射
    • 市場走向
    • 市場預測

第 11 章：市場區隔：按配銷通路

  • 醫院藥房
    • 市場走向
    • 市場預測
  • 零售藥局
    • 市場走向
    • 市場預測
  • 藥局
    • 市場走向
    • 市場預測
  • 其他
    • 市場走向
    • 市場預測

第 12 章：市場區隔：按地區

  • 北美洲
    • 美國
    • 加拿大
  • 亞太
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲
    • 市場走向
    • 市場細分：按國家/地區
    • 市場預測

第 13 章：SWOT 分析

  • 概述
  • 優勢
  • 弱點
  • 機會
  • 威脅

第 14 章：價值鏈分析

第 15 章：波特五力分析

  • 概述
  • 買家的議價能力
  • 供應商的議價能力
  • 競爭程度
  • 新進入者的威脅
  • 替代品的威脅

第 16 章：價格分析

第17章：競爭格局

  • 市場結構
  • 關鍵參與者
  • 關鍵參與者簡介
    • Abbott Laboratories
    • AbbVie Inc.
    • AstraZeneca plc
    • Bristol-Myers Squibb Company
    • Eli Lilly and Company
    • F. Hoffmann-La Roche Ltd.
    • GlaxoSmithKline plc
    • Johnson & Johnson
    • Merck & Co. Inc.
    • Pfizer Inc.
    • Takeda Pharmaceutical Company Limited
    • Teva Pharmaceutical Industries Ltd.
Product Code: SR112024A5663

The global ulcerative colitis market size reached US$ 7.8 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 12.2 Billion by 2032, exhibiting a growth rate (CAGR) of 5.02% during 2024-2032. The ulcerative colitis market is expanding due to rising disease prevalence, advancements in medical treatments, supportive government policies, and increasing global awareness, which drive the demand for innovative therapies in developed and developing regions.

Ulcerative Colitis Market Analysis:

Major Market Drivers: The surging number of ulcerative colitis globally, and the awareness about the existence of inflammatory bowel diseases, stimulate the demand for innovative treatments and diagnostic methods among patients. In addition, technological progress, the expansion of biologics and the invention of new therapies intensify market development. The growing expenditure on healthcare in developed and developing countries also promotes market enlargement.

Key Market Trends: There is an increasing trend toward personalized medicine in treating ulcerative colitis, emphasizing customized therapeutic methods based on genetic, environmental, and phenotypic characteristics. Furthermore, the increased adoption of biologics and biosimilars for managing severe cases is significantly influencing the direction of the pharmaceutical industry in this market.

Geographical Trends: North America leads the ulcerative colitis market due to advanced healthcare facilities, high healthcare expenditure, and established pharmaceutical companies. However, Asia Pacific is anticipated to develop at a significant rate, given the increased health facilities, patient awareness, and medical tourism centering the region, such as China and India.

Competitive Landscape: Some of the major market players in the ulcerative colitis industry include Abbott Laboratories, AbbVie Inc., AstraZeneca plc, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Johnson & Johnson, Merck & Co. Inc., Pfizer Inc., Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Ltd. among many others.

Challenges and Opportunities: The primary challenge of the market is the high cost of treatment, which may create barriers to access in low-income countries, particularly when biologics are involved. Another factor is the labor-intensive and lengthy drug approval process, which could delay new treatments from entering the market. Despite its severity, the challenge can serve as a basis for opportunities. Developing cost-effective therapies and streamlining the approval process can become beneficial for businesses across the globe.

Ulcerative Colitis Market Trends:

Increasing Prevalence of Ulcerative Colitis

The growth in the prevalence of ulcerative colitis, as well as the spread of awareness about the existence of inflammatory bowel diseases, stimulates the demand for innovative treatments and diagnostic methods among patients. In addition, technological progress, the expansion of biologics, and the invention of new therapies intensify market development. The growing expenditure on healthcare in developed and developing countries also promotes market enlargement. According to the NATIONAL LIBRARY OF MEDICINE, ulcerative colitis has an incidence of 9 to 20 cases per 100,000 persons per year. Its prevalence is 156 to 291 cases per 100,000 persons per year.

Advancements in Medical Treatments

Medical treatment of ulcerative colitis has come a long way with the development of biologics and small-molecule drugs. The positive spirit brought about by this progress has created more favorable market-related factors. On the one hand, advances in diagnostic technologies and the development of new targeted treatment approaches have positively affected the market due to increased adoption driven by the development of more effective treatments. For instance, Pfizer Inc. in 2023 announced that the U.S. Food and Drug Administration (FDA) has approved VELSIPITY(TM) (etrasimod), an oral, once-daily, selective sphingosine-1-phosphate (S1P) receptor modulator for adults with moderately to severely active ulcerative colitis (UC).

Government and Regulatory Support

Favorable government policies and increased healthcare spending significantly impact the ulcerative colitis market growth. With regulatory approvals facilitating the rapid market entry of new and effective drugs, patients gain access to advanced treatment options. Additionally, several governments have ramped up funding for research and development, encouraging pharmaceutical companies to invest in innovative therapies for ulcerative colitis, which further stimulates market growth.

Ulcerative Colitis Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the global, regional, and country levels for 2024-2032. Our report has categorized the market based on type, disease type, molecule type, drug type, route of administration, and distribution channel.

Breakup by Type:

Mild UC

Moderate UC

Severe UC

Mild UC accounts for the majority of the market share

The report has provided a detailed breakup and analysis of the market based on the type. This includes mild UC, moderate UC, and severe UC. According to the report, mild UC represented the largest segment.

The mild ulcerative colitis segment dominates owing to the greater prevalence of mild cases compared to moderate and severe forms. Patients with mild UC generally experience fewer symptoms, which can typically be managed with oral medications, such as aminosalicylates. It benefits from numerous first-line treatment options that are less expensive and have fewer side effects, making them accessible and favored by patients and healthcare providers. The availability of effective and affordable treatments contributes significantly to the dominance of this segment in increasing the overall ulcerative colitis market demand. Mild ulcerative colitis is treated with mesalamine (5-aminosalicylic acid, 5-ASA) and other UC medications across all countries. As per the American College of Gastroenterology (ACG) treatment instruction, ulcerative colitis (UC) is categorized as mild in patients who have fewer than four (4) bowel movements per day, minimal bleeding, and no appreciable urgency or abdominal pain. In comparative studies of 2.4 g and 4.8 g daily doses of mesalamine, it was found that patients with mild disease will improve with 2.4 g and 4.8 g doses of mesalamine.

Breakup by Disease Type:

Ulcerative Proctitis

Proctosigmoiditis

Left-sided Colitis

Pancolitis or Universal Colitis

Fulminant Colitis

Ulcerative proctitis holds the largest share in the industry

A detailed breakup and analysis of the market based on the disease type have also been provided in the report. This includes ulcerative proctitis, proctosigmoiditis, left-sided colitis, pancolitis or universal colitis, and fulminant colitis. According to the report, ulcerative proctitis accounted for the largest market share.

Ulcerative proctitis is considered the mildest due to the inflammation being confined to the rectum. Patients usually experience such symptoms as rectal bleeding, urgency, and tenesmus. As per the study by Matthew Mutch, in Shackelford's Surgery of the Alimentary Tract, 2 Volume Set (Eighth Edition), 2019, patients with ulcerative pancolitis for more than 8 years are at higher risk of colorectal cancer, with the risk ranging from 0.5% to 1% per year. The localized nature of symptoms is why it is easier to treat the condition with medicines that require the closest interaction with the perished area rather than using more invasive and less patient-friendly systemic treatment. The focused treatment combines fewer systemic side effects, which is why patients prefer using suppositories or enemas as treatment. Facing better treatment opportunities, patients with ulcerative proctitis have a very good prognosis. Hence, the demand for quality treatments is growing.

Breakup by Molecule Type:

Small Molecules

Biologics

Biologics represents the leading market segment

The report has provided a detailed breakup and analysis of the market based on the molecule type. This includes small molecules and biologics. According to the report, biologics represented the largest segment.

Biologics represent the largest segment in the market. The key reasons for the popularity of this therapy type involve its high efficiency in reducing inflammation and achieving and maintaining remission in patients suffering from moderate to severe disease. These protein-containing drugs work by aiming at particular parts of the immune system that encourage developing inflammation in the body. The increasing demand for biologics is explained by the growing number of approvals and biosimilars, which will make these drugs more available and less costly. For illustration purposes, in March 2024, Johnson & Johnson unveiled the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration pursuing approval of TREMFYA(R) (guselkumab) to treat adult patients with moderately to severely active ulcerative colitis. It is supported by data from the Phase 3 QUASAR program evaluating the efficacy and safety of TREMFYA(R) to treat patients with moderately to severely active UC who had an inadequate response or intolerance to traditional therapy, prior biologics and/or JAK inhibitors.

Breakup by Drug Type:

Anti-Inflammatory Drugs

Anti-TNF Biologics

Immunosuppressant

Calcineurin Inhibitors

Others

Anti-TNF biologics exhibits a clear dominance in the market

A detailed breakup and analysis of the market based on the drug type have also been provided in the report. This includes anti-inflammatory drugs, anti-TNF biologics, immunosuppressant, calcineurin inhibitors, and others. According to the report, anti-TNF biologics accounted for the largest market share.

The market is currently dominated by anti-TNF biologics, primarily due to their ability to control inflammation and sustain remission in patients with moderate-to-severe conditions. Anti-TNF biologics are accustomed to neutralizing the action of a protein in the body known as TNF that causes inflammation, making them a preferable option for patients who are not treated with monotherapy. In addition, the established success of anti-TNF biologics in patient quality of life would agree with these results, despite concerns about costs and side effects.

Breakup by Route of Administration:

Oral

Injectable

Injectable dominates the market

The report has provided a detailed breakup and analysis of the market based on the route of administration. This includes oral and injectable. According to the report, injectables represented the largest segment.

Injectable medications hold a prominent position in the ulcerative colitis market revenue, primarily due to their capacity to deliver treatments directly to the bloodstream, effectively bypassing the digestive system. This category includes biologics such as infliximab and adalimumab, which are particularly used for moderate to severe cases. The preference for injectables stems from their rapid action and high efficacy, especially beneficial for patients who do not respond to oral medications. Additionally, the less frequent dosing requirement compared to oral medications enhances the appeal of injectables, making them a popular choice in managing ulcerative colitis and contributing to their substantial market share. Top of FormFor instance, in 2023, the Food and Drug Administration (FDA) indicated that the subcutaneous administration of vedolizumab is an approvable maintenance therapy for moderate to severe ulcerative colitis following intravenous infusion. It is the only FDA-approved biologic in ulcerative colitis maintenance therapy that is based on IV and SC dose-approved medication.

Breakup by Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Drug Store

Others

Hospital pharmacies are the predominant market segment

A detailed breakup and analysis of the market based on the distribution channel have also been provided in the report. This includes hospital pharmacies, retail pharmacies, drug store, and others. According to the report, hospital pharmacies accounted for the largest market share.

Hospital pharmacies constitute the largest segment in the ulcerative colitis market forecast. Their pivotal role in distributing treatments stems from their proximity to patient care settings and their responsibilities in administering and monitoring therapies. Hospitals are often the first to receive new drug approvals, positioning them as primary channels for distributing advanced therapeutics. This segment benefits from direct interactions with pharmaceutical manufacturers and often engages in price negotiations, which can significantly influence treatment accessibility and adoption rates among patients. For instance, the Apollo Hospital pharmacy business is about to touch 10,000 crore in revenue this year with 5,790 pharmacies, Apollo is the largest pharmacy chain, adding 400-500 stores each year.

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

North America leads the market, accounting for the largest ulcerative colitis market share

The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.

North America dominates the ulcerative colitis market on account of the high occurrence of the disorder, superior medical facilities, and extensive funding for R&D activities. The American and Canadian health systems ensure the substantial usage of progressive treatments, and private insurance plans and campaigns further enhance the consumer understanding of products. Companies in the pharmaceutical and biotech sectors accelerate the development of innovative treatment methods. They integrate the most successful ones into their treatment protocols at an early stage, advancing the market. At present, ulcerative colitis has an incidence of 9 to 20 cases per 100,000 persons per year and 156 to 291 cases per 100,000 persons per year as per National Institute of Health (NIH). Ulcerative colitis market recent opportunities include numerous key players collaborating to expand their market growth. For instance, Teva Pharmaceuticals, a U.S. subsidiary of Teva Pharmaceuticals Industries Ltd., and Sanofi collaborated to create and co-commercialize asset TEV'574, to treat Ulcerative Colitis and Crohn's Disease.

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the major market players in the keyword industry include Abbott Laboratories, AbbVie Inc., AstraZeneca plc, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Johnson & Johnson, Merck & Co. Inc., Pfizer Inc., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd.

(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)

Leading players in the ulcerative colitis market recent developments include the development of advanced biologics and small molecule therapies, improved drug delivery systems, and expansion into untapped markets. The leading players are also involved in strategic initiatives such as partnerships, mergers, acquisitions, and increasing investment in research and innovation to enhance treatment efficacies. These efforts are aimed at boosting market share and addressing the unmet needs in ulcerative colitis management. Besides this, Pfizer Inc. unveiled that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for VELSIPITY(TM) (etrasimod), an oral, once-daily, selective sphingosine-1-phosphate (S1P) receptor modulator. This medication is intended for the treatment of patients aged 16 and older with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biological agent.

Latest News:

November 2021: Bristol Myers Squibb received European Commission approval for Zeposia (ozanimod) for the treatment of adults with moderately to severely active ulcerative colitis.Top of Form

March 2024: AbbVie Inc., and Landos Biopharma Inc. unveiled that AbbVie entered into a definitive agreement that provides for the acquisition of Landos, a clinical-stage biopharmaceutical corporation keen on developing advanced novel oral therapeutics for individuals with autoimmune disorders.

Key Questions Answered in This Report:

  • How has the global ulcerative colitis market performed so far, and how will it perform in the coming years?
  • What are the drivers, restraints, and opportunities in the global ulcerative colitis market?
  • What is the impact of each driver, restraint, and opportunity on the global ulcerative colitis market?
  • What are the key regional markets?
  • Which countries represent the most attractive ulcerative colitis market?
  • What is the breakup of the market based on the type?
  • Which is the most attractive type in the ulcerative colitis market?
  • What is the breakup of the market based on the disease type?
  • Which is the most attractive disease type in the ulcerative colitis market?
  • What is the breakup of the market based on the molecule type?
  • Which is the most attractive molecule type in the ulcerative colitis market?
  • What is the breakup of the market based on the drug type?
  • Which is the most attractive drug type in the ulcerative colitis market?
  • What is the breakup of the market based on the route of administration?
  • Which is the most attractive route of administration in the ulcerative colitis market?
  • What is the breakup of the market based on the distribution channel?
  • Which is the most attractive distribution channel in the ulcerative colitis market?
  • What is the competitive structure of the market?
  • Who are the key players/companies in the global ulcerative colitis market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Ulcerative Colitis Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Type

  • 6.1 Mild UC
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Moderate UC
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Severe UC
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast

7 Market Breakup by Disease Type

  • 7.1 Ulcerative Proctitis
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Proctosigmoiditis
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Left-sided Colitis
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Pancolitis or Universal Colitis
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Fulminant Colitis
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast

8 Market Breakup by Molecule Type

  • 8.1 Small Molecules
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Biologics
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast

9 Market Breakup by Drug Type

  • 9.1 Anti-Inflammatory Drugs
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Anti-TNF Biologics
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Immunosuppressant
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast
  • 9.4 Calcineurin Inhibitors
    • 9.4.1 Market Trends
    • 9.4.2 Market Forecast
  • 9.5 Others
    • 9.5.1 Market Trends
    • 9.5.2 Market Forecast

10 Market Breakup by Route of Administration

  • 10.1 Oral
    • 10.1.1 Market Trends
    • 10.1.2 Market Forecast
  • 10.2 Injectable
    • 10.2.1 Market Trends
    • 10.2.2 Market Forecast

11 Market Breakup by Distribution Channel

  • 11.1 Hospital Pharmacies
    • 11.1.1 Market Trends
    • 11.1.2 Market Forecast
  • 11.2 Retail Pharmacies
    • 11.2.1 Market Trends
    • 11.2.2 Market Forecast
  • 11.3 Drug Store
    • 11.3.1 Market Trends
    • 11.3.2 Market Forecast
  • 11.4 Others
    • 11.4.1 Market Trends
    • 11.4.2 Market Forecast

12 Market Breakup by Region

  • 12.1 North America
    • 12.1.1 United States
      • 12.1.1.1 Market Trends
      • 12.1.1.2 Market Forecast
    • 12.1.2 Canada
      • 12.1.2.1 Market Trends
      • 12.1.2.2 Market Forecast
  • 12.2 Asia-Pacific
    • 12.2.1 China
      • 12.2.1.1 Market Trends
      • 12.2.1.2 Market Forecast
    • 12.2.2 Japan
      • 12.2.2.1 Market Trends
      • 12.2.2.2 Market Forecast
    • 12.2.3 India
      • 12.2.3.1 Market Trends
      • 12.2.3.2 Market Forecast
    • 12.2.4 South Korea
      • 12.2.4.1 Market Trends
      • 12.2.4.2 Market Forecast
    • 12.2.5 Australia
      • 12.2.5.1 Market Trends
      • 12.2.5.2 Market Forecast
    • 12.2.6 Indonesia
      • 12.2.6.1 Market Trends
      • 12.2.6.2 Market Forecast
    • 12.2.7 Others
      • 12.2.7.1 Market Trends
      • 12.2.7.2 Market Forecast
  • 12.3 Europe
    • 12.3.1 Germany
      • 12.3.1.1 Market Trends
      • 12.3.1.2 Market Forecast
    • 12.3.2 France
      • 12.3.2.1 Market Trends
      • 12.3.2.2 Market Forecast
    • 12.3.3 United Kingdom
      • 12.3.3.1 Market Trends
      • 12.3.3.2 Market Forecast
    • 12.3.4 Italy
      • 12.3.4.1 Market Trends
      • 12.3.4.2 Market Forecast
    • 12.3.5 Spain
      • 12.3.5.1 Market Trends
      • 12.3.5.2 Market Forecast
    • 12.3.6 Russia
      • 12.3.6.1 Market Trends
      • 12.3.6.2 Market Forecast
    • 12.3.7 Others
      • 12.3.7.1 Market Trends
      • 12.3.7.2 Market Forecast
  • 12.4 Latin America
    • 12.4.1 Brazil
      • 12.4.1.1 Market Trends
      • 12.4.1.2 Market Forecast
    • 12.4.2 Mexico
      • 12.4.2.1 Market Trends
      • 12.4.2.2 Market Forecast
    • 12.4.3 Others
      • 12.4.3.1 Market Trends
      • 12.4.3.2 Market Forecast
  • 12.5 Middle East and Africa
    • 12.5.1 Market Trends
    • 12.5.2 Market Breakup by Country
    • 12.5.3 Market Forecast

13 SWOT Analysis

  • 13.1 Overview
  • 13.2 Strengths
  • 13.3 Weaknesses
  • 13.4 Opportunities
  • 13.5 Threats

14 Value Chain Analysis

15 Porters Five Forces Analysis

  • 15.1 Overview
  • 15.2 Bargaining Power of Buyers
  • 15.3 Bargaining Power of Suppliers
  • 15.4 Degree of Competition
  • 15.5 Threat of New Entrants
  • 15.6 Threat of Substitutes

16 Price Analysis

17 Competitive Landscape

  • 17.1 Market Structure
  • 17.2 Key Players
  • 17.3 Profiles of Key Players
    • 17.3.1 Abbott Laboratories
      • 17.3.1.1 Company Overview
      • 17.3.1.2 Product Portfolio
      • 17.3.1.3 Financials
      • 17.3.1.4 SWOT Analysis
    • 17.3.2 AbbVie Inc.
      • 17.3.2.1 Company Overview
      • 17.3.2.2 Product Portfolio
      • 17.3.2.3 Financials
      • 17.3.2.4 SWOT Analysis
    • 17.3.3 AstraZeneca plc
      • 17.3.3.1 Company Overview
      • 17.3.3.2 Product Portfolio
      • 17.3.3.3 Financials
      • 17.3.3.4 SWOT Analysis
    • 17.3.4 Bristol-Myers Squibb Company
      • 17.3.4.1 Company Overview
      • 17.3.4.2 Product Portfolio
      • 17.3.4.3 Financials
      • 17.3.4.4 SWOT Analysis
    • 17.3.5 Eli Lilly and Company
      • 17.3.5.1 Company Overview
      • 17.3.5.2 Product Portfolio
      • 17.3.5.3 Financials
      • 17.3.5.4 SWOT Analysis
    • 17.3.6 F. Hoffmann-La Roche Ltd.
      • 17.3.6.1 Company Overview
      • 17.3.6.2 Product Portfolio
      • 17.3.6.3 Financials
    • 17.3.7 GlaxoSmithKline plc
      • 17.3.7.1 Company Overview
      • 17.3.7.2 Product Portfolio
      • 17.3.7.3 Financials
      • 17.3.7.4 SWOT Analysis
    • 17.3.8 Johnson & Johnson
      • 17.3.8.1 Company Overview
      • 17.3.8.2 Product Portfolio
      • 17.3.8.3 Financials
      • 17.3.8.4 SWOT Analysis
    • 17.3.9 Merck & Co. Inc.
      • 17.3.9.1 Company Overview
      • 17.3.9.2 Product Portfolio
      • 17.3.9.3 Financials
      • 17.3.9.4 SWOT Analysis
    • 17.3.10 Pfizer Inc.
      • 17.3.10.1 Company Overview
      • 17.3.10.2 Product Portfolio
      • 17.3.10.3 Financials
      • 17.3.10.4 SWOT Analysis
    • 17.3.11 Takeda Pharmaceutical Company Limited
      • 17.3.11.1 Company Overview
      • 17.3.11.2 Product Portfolio
      • 17.3.11.3 Financials
      • 17.3.11.4 SWOT Analysis
    • 17.3.12 Teva Pharmaceutical Industries Ltd.
      • 17.3.12.1 Company Overview
      • 17.3.12.2 Product Portfolio
      • 17.3.12.3 Financials
      • 17.3.12.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Ulcerative Colitis Market: Major Drivers and Challenges
  • Figure 2: Global: Ulcerative Colitis Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Ulcerative Colitis Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 4: Global: Ulcerative Colitis Market: Breakup by Type (in %), 2023
  • Figure 5: Global: Ulcerative Colitis Market: Breakup by Disease Type (in %), 2023
  • Figure 6: Global: Ulcerative Colitis Market: Breakup by Molecule Type (in %), 2023
  • Figure 7: Global: Ulcerative Colitis Market: Breakup by Drug Type (in %), 2023
  • Figure 8: Global: Ulcerative Colitis Market: Breakup by Route of Administration (in %), 2023
  • Figure 9: Global: Ulcerative Colitis Market: Breakup by Distribution Channel (in %), 2023
  • Figure 10: Global: Ulcerative Colitis Market: Breakup by Region (in %), 2023
  • Figure 11: Global: Ulcerative Colitis (Mild UC) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 12: Global: Ulcerative Colitis (Mild UC) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 13: Global: Ulcerative Colitis (Moderate UC) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 14: Global: Ulcerative Colitis (Moderate UC) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 15: Global: Ulcerative Colitis (Severe UC) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 16: Global: Ulcerative Colitis (Severe UC) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 17: Global: Ulcerative Colitis (Ulcerative Proctitis) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 18: Global: Ulcerative Colitis (Ulcerative Proctitis) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 19: Global: Ulcerative Colitis (Proctosigmoiditis) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 20: Global: Ulcerative Colitis (Proctosigmoiditis) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 21: Global: Ulcerative Colitis (Left-sided Colitis) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 22: Global: Ulcerative Colitis (Left-sided Colitis) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 23: Global: Ulcerative Colitis (Pancolitis or Universal Colitis) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 24: Global: Ulcerative Colitis (Pancolitis or Universal Colitis) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 25: Global: Ulcerative Colitis (Fulminant Colitis) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 26: Global: Ulcerative Colitis (Fulminant Colitis) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 27: Global: Ulcerative Colitis (Small Molecules) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 28: Global: Ulcerative Colitis (Small Molecules) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 29: Global: Ulcerative Colitis (Biologics) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 30: Global: Ulcerative Colitis (Biologics) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 31: Global: Ulcerative Colitis (Anti-Inflammatory Drugs) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 32: Global: Ulcerative Colitis (Anti-Inflammatory Drugs) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 33: Global: Ulcerative Colitis (Anti-TNF Biologics) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 34: Global: Ulcerative Colitis (Anti-TNF Biologics) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 35: Global: Ulcerative Colitis (Immunosuppressant) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 36: Global: Ulcerative Colitis (Immunosuppressant) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 37: Global: Ulcerative Colitis (Calcineurin Inhibitors) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 38: Global: Ulcerative Colitis (Calcineurin Inhibitors) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 39: Global: Ulcerative Colitis (Other Drug Types) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 40: Global: Ulcerative Colitis (Other Drug Types) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 41: Global: Ulcerative Colitis (Oral) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 42: Global: Ulcerative Colitis (Oral) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 43: Global: Ulcerative Colitis (Injectable) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 44: Global: Ulcerative Colitis (Injectable) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 45: Global: Ulcerative Colitis (Hospital Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 46: Global: Ulcerative Colitis (Hospital Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 47: Global: Ulcerative Colitis (Retail Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 48: Global: Ulcerative Colitis (Retail Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 49: Global: Ulcerative Colitis (Drug Store) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 50: Global: Ulcerative Colitis (Drug Store) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 51: Global: Ulcerative Colitis (Other Distribution Channels) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 52: Global: Ulcerative Colitis (Other Distribution Channels) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 53: North America: Ulcerative Colitis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 54: North America: Ulcerative Colitis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 55: United States: Ulcerative Colitis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 56: United States: Ulcerative Colitis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 57: Canada: Ulcerative Colitis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 58: Canada: Ulcerative Colitis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 59: Asia-Pacific: Ulcerative Colitis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 60: Asia-Pacific: Ulcerative Colitis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 61: China: Ulcerative Colitis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 62: China: Ulcerative Colitis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 63: Japan: Ulcerative Colitis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 64: Japan: Ulcerative Colitis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 65: India: Ulcerative Colitis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 66: India: Ulcerative Colitis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 67: South Korea: Ulcerative Colitis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 68: South Korea: Ulcerative Colitis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 69: Australia: Ulcerative Colitis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 70: Australia: Ulcerative Colitis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 71: Indonesia: Ulcerative Colitis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 72: Indonesia: Ulcerative Colitis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 73: Others: Ulcerative Colitis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 74: Others: Ulcerative Colitis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 75: Europe: Ulcerative Colitis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 76: Europe: Ulcerative Colitis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 77: Germany: Ulcerative Colitis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 78: Germany: Ulcerative Colitis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 79: France: Ulcerative Colitis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 80: France: Ulcerative Colitis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 81: United Kingdom: Ulcerative Colitis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 82: United Kingdom: Ulcerative Colitis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 83: Italy: Ulcerative Colitis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 84: Italy: Ulcerative Colitis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 85: Spain: Ulcerative Colitis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 86: Spain: Ulcerative Colitis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 87: Russia: Ulcerative Colitis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 88: Russia: Ulcerative Colitis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 89: Others: Ulcerative Colitis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 90: Others: Ulcerative Colitis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 91: Latin America: Ulcerative Colitis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 92: Latin America: Ulcerative Colitis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 93: Brazil: Ulcerative Colitis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 94: Brazil: Ulcerative Colitis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 95: Mexico: Ulcerative Colitis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 96: Mexico: Ulcerative Colitis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 97: Others: Ulcerative Colitis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 98: Others: Ulcerative Colitis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 99: Middle East and Africa: Ulcerative Colitis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 100: Middle East and Africa: Ulcerative Colitis Market: Breakup by Country (in %), 2023
  • Figure 101: Middle East and Africa: Ulcerative Colitis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 102: Global: Ulcerative Colitis Industry: SWOT Analysis
  • Figure 103: Global: Ulcerative Colitis Industry: Value Chain Analysis
  • Figure 104: Global: Ulcerative Colitis Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Ulcerative Colitis Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Ulcerative Colitis Market Forecast: Breakup by Type (in Million US$), 2024-2032
  • Table 3: Global: Ulcerative Colitis Market Forecast: Breakup by Disease Type (in Million US$), 2024-2032
  • Table 4: Global: Ulcerative Colitis Market Forecast: Breakup by Molecule Type (in Million US$), 2024-2032
  • Table 5: Global: Ulcerative Colitis Market Forecast: Breakup by Drug Type (in Million US$), 2024-2032
  • Table 6: Global: Ulcerative Colitis Market Forecast: Breakup by Route of Administration (in Million US$), 2024-2032
  • Table 7: Global: Ulcerative Colitis Market Forecast: Breakup by Distribution Channel (in Million US$), 2024-2032
  • Table 8: Global: Ulcerative Colitis Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 9: Global: Ulcerative Colitis Market: Competitive Structure
  • Table 10: Global: Ulcerative Colitis Market: Key Players